FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2543403710> ?p ?o ?g. }

• W2543403710 abstract "Abstract The aim of the present study was to evaluate retrospectively the clinical outcome of 2 consecutive cohorts of relapsed/refractory NHL patients treated with HDS chemotherapy with and without Rituximab and autologous peripheral blood stem cell (PBSC) transplantation. A total of 110 relapsed or refractory NHL patients with different histology (SLL n= 4, FL n=24, Low grade-transformed n=31, DLBCL n=51) entered this analysis. From October 1992 up to November 2004, patients were treated with the original HDS program (n= 33, HDS: cyclophosphamide 7 gr/sqm, methotrexate 8 gr/sqm, etoposide 2 gr/sqm) (Gianni AM et al.: N.Engl.J.Med., 1997) or a modified version (n= 15) in which methotrexate was replaced by HD-Ara-C (2 g/sqm every 12 hours for 6 days). Because the addition of Rituximab could improve the antitumor activity and the response rate before transplantation, from June 1999, Rituximab (375 mg /sqm) was given twice after HD-CTX and twice after HD-Ara-C. Following the HDS chemotherapy program, a BEAM (carmustine BCNU, 300 mg/sqm; etoposide, 200 mg/sqm; Ara-C, 4000 mg/sqm; L-PAM 140 mg/sqm) conditioning regimen with autologous PBSC transplantation was planned. By quantitative PCR analysis of BCL2/IgH chimeric gene, a molecular evaluation of minimal residual disease was performed before transplantation and during follow up on bone marrow or peripheral blood obtained from 21 patients. At enrollment, 69 patients (63%) were high risk being primary refractory (39), early relapsed (7) after first line treatment or relapsed more than twice (23). Moreover, an IPI >1 was documented in 62 patients (56%) and a bone marrow infiltration in 42 (38%). Sixteen patients (15%) had received 2 or 3 lines of conventional chemotherapy and 29 (26%) involved field Radiotherapy. At the end of HDS chemotherapy, before the conditioning regimen, the Response Rate was 82% with 76 patients achieving complete remission (CR, 69%) and 14 patients partial remission (PR, 13%). After autologous transplantation, 76 patients remained in CR (69%), 5 in PR (5%), 25 (23%) showed no response or progressive disease. Four patients (3%) died during treatment. Ninety-four patients (85%) could complete the planned program and underwent autologous transplantation and a median number of 6.3 x 10^6 cells CD34+/Kg was transplanted. After transplantation, 24 patients relapsed, 1 patient developed secondary MDS and 1 patient died because of a secondary GI tract solid tumor. With a median follow-up of 28 months (range 3–146), the 5-year estimate overall survival (OS) and event-free survival (EFS) of the whole group of patients is 48% and 39%, respectively. However, the EFS of patients not receiving Rituximab was 27% as compared to 55% registered in the R-HDS program (p= 0.005). The Cox multivariate analysis confirmed an improved OS (p=0.0000) and EFS (0.001) for patients treated with R-HDS. The achievement of a durable molecular remission was achieved in 11 out of 21 analyzed and was strongly associated with the R-HDS program. In conclusion: the response rate of relapsed or refractory NHL after HDS chemotherapy is high and more than 70% of patients can undergo conditioning regimen and autologous transplantation being in complete remission. The addition of Rituximab to HDS chemotherapy allows the collection of tumor free PBSC in most patients and significantly correlates with an improved Event Free Survival and Overall Survival." @default.
• W2543403710 created "2016-11-04" @default.
• W2543403710 creator A5001591385 @default.
• W2543403710 creator A5023382026 @default.
• W2543403710 creator A5038898384 @default.
• W2543403710 creator A5051021130 @default.
• W2543403710 creator A5055401685 @default.
• W2543403710 creator A5069072959 @default.
• W2543403710 date "2005-11-16" @default.
• W2543403710 modified "2023-09-27" @default.
• W2543403710 title "The Addition of Rituximab to High Dose Sequential Chemotherapy (HDS) Programs with Autologous Transplantation Significantly Improves the Outcome of Patients with Refractory or Relapsed B-Cell Non Hogkin’s Lymphoma." @default.
• W2543403710 doi "https://doi.org/10.1182/blood.v106.11.2084.2084" @default.
• W2543403710 hasPublicationYear "2005" @default.
• W2543403710 type Work @default.
• W2543403710 sameAs 2543403710 @default.
• W2543403710 citedByCount "0" @default.
• W2543403710 crossrefType "journal-article" @default.
• W2543403710 hasAuthorship W2543403710A5001591385 @default.
• W2543403710 hasAuthorship W2543403710A5023382026 @default.
• W2543403710 hasAuthorship W2543403710A5038898384 @default.
• W2543403710 hasAuthorship W2543403710A5051021130 @default.
• W2543403710 hasAuthorship W2543403710A5055401685 @default.
• W2543403710 hasAuthorship W2543403710A5069072959 @default.
• W2543403710 hasConcept C121332964 @default.
• W2543403710 hasConcept C126322002 @default.
• W2543403710 hasConcept C141071460 @default.
• W2543403710 hasConcept C142424586 @default.
• W2543403710 hasConcept C2776694085 @default.
• W2543403710 hasConcept C2776755627 @default.
• W2543403710 hasConcept C2778119113 @default.
• W2543403710 hasConcept C2779263901 @default.
• W2543403710 hasConcept C2779338263 @default.
• W2543403710 hasConcept C2780147359 @default.
• W2543403710 hasConcept C2780653079 @default.
• W2543403710 hasConcept C2781413609 @default.
• W2543403710 hasConcept C2911091166 @default.
• W2543403710 hasConcept C71924100 @default.
• W2543403710 hasConcept C87355193 @default.
• W2543403710 hasConcept C90924648 @default.
• W2543403710 hasConceptScore W2543403710C121332964 @default.
• W2543403710 hasConceptScore W2543403710C126322002 @default.
• W2543403710 hasConceptScore W2543403710C141071460 @default.
• W2543403710 hasConceptScore W2543403710C142424586 @default.
• W2543403710 hasConceptScore W2543403710C2776694085 @default.
• W2543403710 hasConceptScore W2543403710C2776755627 @default.
• W2543403710 hasConceptScore W2543403710C2778119113 @default.
• W2543403710 hasConceptScore W2543403710C2779263901 @default.
• W2543403710 hasConceptScore W2543403710C2779338263 @default.
• W2543403710 hasConceptScore W2543403710C2780147359 @default.
• W2543403710 hasConceptScore W2543403710C2780653079 @default.
• W2543403710 hasConceptScore W2543403710C2781413609 @default.
• W2543403710 hasConceptScore W2543403710C2911091166 @default.
• W2543403710 hasConceptScore W2543403710C71924100 @default.
• W2543403710 hasConceptScore W2543403710C87355193 @default.
• W2543403710 hasConceptScore W2543403710C90924648 @default.
• W2543403710 hasLocation W25434037101 @default.
• W2543403710 hasOpenAccess W2543403710 @default.
• W2543403710 hasPrimaryLocation W25434037101 @default.
• W2543403710 hasRelatedWork W1987997012 @default.
• W2543403710 hasRelatedWork W2028647548 @default.
• W2543403710 hasRelatedWork W2121694206 @default.
• W2543403710 hasRelatedWork W2362661449 @default.
• W2543403710 hasRelatedWork W2370952297 @default.
• W2543403710 hasRelatedWork W2563189124 @default.
• W2543403710 hasRelatedWork W2575619275 @default.
• W2543403710 hasRelatedWork W289249146 @default.
• W2543403710 hasRelatedWork W2913496777 @default.
• W2543403710 hasRelatedWork W3032811446 @default.
• W2543403710 isParatext "false" @default.
• W2543403710 isRetracted "false" @default.
• W2543403710 magId "2543403710" @default.
• W2543403710 workType "article" @default.